Idiopathic inflammatory myopathies C. treatment and assessment

Primer on the Rheumatic Diseases: Thirteenth Edition

Volumn , Issue , 2008, Pages 375-380

  Oddis, Chester V ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892318267     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-68566-3_48     Document Type: Chapter

References (19)

1. Miller FW, Rider LG, Chung YL, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology 2001;40:1262-1273.
2. Rider LG, Giannini EH, Brunner HI, et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004;50:2281-2290.
3. Oddis CV, Rider LG, Reed AM, et al. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 2005;52:2607-2615.
4. Guzman J, Petty RE, Malleson PN. Monitoring disease activity in juvenile dermatomyositis: the role of von Will-ebrand factor and muscle enzymes. J. Rheumatol 1994;21:739-743.
5. Johnston JD, Lloyd M, Mathews JA, et al. Racial variation in serum creatine kinase levels. J Roy Soc Med 1996;89: 462-464.
6. Scott DL, Kingsley GH. Use of imaging to assess patients with muscle disease. Curr Opin Rheumatol 2004;16: 678-683.
7. Dion E, Cherin P, Payan C, et al. Magnetic resonance imaging criteria for distinguishing between inclusion body myositis and polymyositis. J Rheumatol 2002;29:1897-1906.
8. Schnabel A, Hellmich B, Gross WL. Interstitial lung disease in polymyositis and dermatomyositis. Curr Rheum Rep 2005;7:99-105.
9. Targoff IN. Idiopathic inflammatory myopathy: autoanti-body update. Curr Rheum Rep 2002;4:434-441.
10. Brouwer R, Hengstman GJ, Egberts WT, et al. Autoanti-body profiles in the sera of European patients with myo-sitis. Ann Rheum Dis 2001;60:116-123.
11. Kao AH, Lacomis DH, Lucas M, et al. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 2004;50:209-215.
12. Hengstman GJ, Brouwer R, Egberts WT, et al. Clinical and serological characteristics of 125 Dutch myositis patients. Myositis-specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies. J Neurol 2002;249:69-75.
13. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001;357:96-100.
14. Baer AN. Advances in the therapy of idiopathic inflam-matory myopathies. Curr Opin Rheumatol 2006;18: 236-241.
15. Villalba L, Hick JE, Adams EM, et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 1998;41:392-399.
16. Wilkes MR, Sereika SM, Fertig N, et al. Treatment of antisynthetase- associated interstitial lung disease with tacrolimus. Arthritis Rheum 2005;52:2439-2446.
17. Barohn RJ, Amato AA, Sahenk Z, et al. Inclusion body myositis: explanation for poor response to immunosup-pressive therapy. Neurology 1995;45:1302-1304.
18. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329: 1993-2000.
19. Levine TD. Rituximab in the treatment of dermatomy-ositis: an open-label pilot study. Arthritis Rheum 2005;52: 601-607.